Tagged with Investment

Puerto Rico Yandia Perez is the executive vice president of the Puerto Rico Manufacturers Association (PRMA), an organization celebrating its 95th anniversary and dedicated to fostering a strong manufacturing ecosystem on the island. Under her leadership, PRMA has prioritized not only the pharmaceutical sector, which constitutes about 30% of Puerto Rico’s GDP,…

Switzerland Adrian Hunn of Swiss Medtech, shares insights into his role and the future of Switzerland’s medtech sector. He discusses the association’s focus on fostering innovation, navigating regulatory challenges, and promoting international collaboration to position Switzerland as a global leader. Hunn highlights key initiatives, such as supporting digital healthcare, sustainability efforts,…

Puerto Rico Ivan Lugo-Montes emphasizes the Puerto Rico Bioscience Cluster (INDUNIV)’s instrumental role in advancing the island’s biosciences industry for over 60 years. Driven by innovation, workforce development, and global competitiveness, the Cluster has achieved significant milestones in advanced manufacturing, pharmaceutical cold chain logistics certification, business promotion, and international partnerships. Key initiatives…

Puerto Rico With lower labour costs than mainland US, but the same regulatory framework and straightforward market access, Puerto Rico has long presented a compelling value proposition for pharmaceutical manufacturing, a sector that accounts for some 30 percent of the island’s GDP.  After bouncing back from bankruptcy, devastating hurricanes and the COVID-19…

Switzerland Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to bridge corporate and governmental interests. He explains his current focus on maintaining the strength of the US-Swiss business relationship, especially…

China The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director Renaud Gabay discusses how member companies are leveraging synchronized approvals to accelerate access; the evolution of China’s regulatory framework that…

Switzerland Swiss Biotech’s Michael Altorfer explains how Switzerland’s biotech industry continues to grow, driven by startups and SMEs and supported by strong international collaborations across the entire value chain. He outlines how Swissmedic’s proactive approach to advanced therapies and participation in the Access Consortium enables faster and more efficient drug approval…

Switzerland Christof Kloepper delves into the Basel Area’s positioning as a leading hub for life sciences and biotech innovation. Kloepper emphasizes the region’s commitment to attracting global companies, nurturing startups, and building a strong ecosystem of talent, research, and infrastructure. He draws a comparison to Boston and highlights the Basel Area’s…

Switzerland Dr Stephan Mumenthaler, director of scienceindustries, highlights Switzerland’s strong position in the healthcare, life sciences, and pharmaceutical sectors and explores the nation’s commitment to innovation, sustainability, and maintaining global competitiveness.   Switzerland remains a premier destination for the healthcare, life sciences, and pharmaceutical industries, consistently ranking among the top countries…

Mexico Pedro Casas Alatriste of AmCham Mexico delves into the chamber’s efforts to enhance U.S.-Mexico trade relations, support key industries, and promote sustainable growth amid Mexico’s political transition.   We are entering North America 2.0, poised for renewed growth and collaboration What are the key issues the American Chamber of Commerce…

Hong Kong Hong Kong’s ambitious plans to transform into an “innovation and technology” hub will require careful and deliberate combinations of Hong Kong and mainland capabilities. From this understanding, the idea for the Hong Kong-Shenzhen Innovation and Technology Park (HSITP) was born. This new science park on the border with Shenzhen is…

Hong Kong It has been an extremely challenging couple of years for Hong Kong’s financial sector, including for the wealth of biotech companies listed in the city, but fundamentals remain strong, and the green shoots of recovery are starting to be seen.   While biotech has historically been a high-risk, high-reward sector,…